Accessibility Menu
MediPharm Labs logo

MediPharm Labs(TSX) LABS

Market CapCA$34.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-96%
5 Year-77%
1 Year-6%
1 Month+0%
CA$0.08
-6.25%
-0.01Today
MediPharm Labs last closing stock price
MetricPriceDate
Last closeCAD 0.082026-08-31
MediPharm Labs stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%CAD 0.082026-08-24
1 month+0%CAD 0.082026-07-31
3 month-6.25%CAD 0.082026-06-02
Year to date+15.38%CAD 0.072025-12-31
1 year-6.25%CAD 0.082025-08-29
3 year+0%CAD 0.082023-09-01
5 year-77.27%CAD 0.332021-09-01
Since inception-96.36%CAD 2.202018-10-05

MediPharm Labs Financials at a Glance

Market Cap

CA$34.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$41.46M

Net Income (TTM)

-CA$4.97M

EPS (TTM)

-CA$0.01

P/E Ratio

-6.78

Dividend

CA$0.00

Beta (Volatility)

0.82 (Low)

Price

CA$0.08

Volume

45,405

Open

CA$0.08

Previous Close

CA$0.08

Daily Range

CA$0.08 - CA$0.08

52-Week Range

CA$0.06 - CA$0.10

Estimated Earnings Date

Aug 13, 2026

LABS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MediPharm Labs

MediPharm Labs Corp. operates as a pharmaceutical entity, specializing in the creation and global commercialization of premium, pharmaceutical-grade cannabis oils, concentrates, and sophisticated derivative products. The company manages the full cycle from developing and processing to packaging and distributing a diverse array of cannabis extracts and advanced cannabinoid-based formulations.

Products and Services
  • Pharmaceutical-grade cannabis oils and concentrates
  • Advanced cannabinoid-based formulations
  • GMP-certified flower procurement and logistics services
Growth Outlook
  • Revenue increased to CAD 9.98 million in Q2 2026
  • Gross profit margin improved to 43% in Q2 2026
  • Expansion into international markets enhances growth potential
Financial Highlights
  • Trailing twelve months revenue of CAD 39.5 million
  • Current ratio of 2.69 indicates strong liquidity position
  • Net income of CAD 4,000 reported in Q2 2026
MediPharm Labs Corp. has established itself as a key player in the cannabis industry, focusing on high-quality products and innovative solutions. The recent revenue growth and improved gross profit margin reflect the company's operational efficiency and market demand. With a strong liquidity position, indicated by a current ratio of 2.69, the company is well-positioned to navigate the evolving landscape of the cannabis market. The expansion into international markets further enhances the growth potential, making MediPharm Labs an intriguing option for investors interested in the pharmaceutical cannabis sector.
AI Generated • Aug 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

127

CEO

Greg Hunter, MBA, CPA

Website

www.medipharmlabs.com

Headquarters

Barrie, ON L4N 2L1, CA

LABS Financials

Key Financial Metrics (TTM)

Gross Margin

34.30%

Operating Margin

-12.49%

Net Income Margin

-12.00%

Return on Equity

-13.79%

Return on Capital

-23.35%

Return on Assets

-10.81%

Earnings Yield

-14.75%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$34.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

427.18M

Volume

45.41K

Avg. Volume

177.57K

Financials (TTM)

Gross Profit

CA$14.22M

Operating Income

-CA$5.18M

EBITDA

-CA$3.50M

Operating Cash Flow

-CA$897.00K

Capital Expenditure

-CA$63.00K

Free Cash Flow

-CA$960.00K

Cash & ST Invst.

CA$9.85M

Total Debt

CA$421.00K

MediPharm Labs Performance Analysis

MediPharm Labs annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 22,117,0001.9%
20232023-12-31CAD 33,062,00049.5%
20242024-12-31CAD 41,961,00026.9%
20252025-12-31CAD 45,124,0007.5%
MediPharm Labs sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-3.0%
Q42025-12-31-3.4%
Q12026-03-31-19.0%
Q22026-06-3011.4%
MediPharm Labs annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.11-50.6%
20232023-12-31CAD -0.04-66.8%
20242024-12-31CAD -0.03-27.2%
20252025-12-31CAD -0.02-24.4%
MediPharm Labs sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3044.0%
Q42025-12-3111.8%
Q12026-03-3155.6%
Q22026-06-30100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$9.98M

-15.4%

Gross Profit

CA$4.29M

+28.9%

Gross Margin

43.00%

N/A

Market Cap

CA$34.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$269.09K

N/A

Employees

127

N/A

Net Income

CA$4.00K

+100.1%

EBITDA

CA$221.00K

+106.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$9.85M

-4.9%

Total Debt

CA$421.00K

-22.3%

Accounts Receivable

CA$7.27M

-9.3%

Inventory

CA$9.81M

+4.9%

Long Term Debt

CA$0.00

-100.0%

Short Term Debt

CA$421.00K

-20.9%

Return on Assets

-10.81%

N/A

Return on Invested Capital

-14.61%

N/A

Free Cash Flow

-CA$442.00K

+84.3%

Operating Cash Flow

-CA$396.00K

+85.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RVX.TOResverlogix Corp.
CA$0.10+0.00%
ROMJ.VRubicon Organics Inc.
CA$0.55-6.78%
AVCN.TOAvicanna Inc.
CA$0.13+0.00%
ADK.VDIAGNOS Inc.
CA$0.50+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About LABS

What is the current price of MediPharm Labs?

MediPharm Labs is trading at CA$0.08 per share.

What is the 52-week range for MediPharm Labs?

Over the past 52 weeks, MediPharm Labs has traded between CA$0.06 and CA$0.10.

How much debt does MediPharm Labs have?

As of the most recent reporting period, MediPharm Labs reported total debt of CA$421.00K.

How much cash does MediPharm Labs have on hand?

MediPharm Labs reported CA$9.85M in cash and cash equivalents in its most recent financial results.

What is MediPharm Labs’s dividend yield?

MediPharm Labs does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services